Abbott Laboratories (NYSE:ABT) is one of the defensive stocks that billionaires are buying amid US trade tariff uncertainty. On July 21, UBS reiterated a ‘Buy’ rating and a $148 price target on the ...

But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. There are plenty of strategies for discovering value stocks, but we have found ...

Abbott Laboratories (NYSE:ABT) has significantly outperformed the broader S&P 500 index this year, with its stock price rising 18% compared to the S&P 500’s 6% gain. This strong performance ...

Abbott Laboratories' second-largest division, diagnostics, continues to be a hindrance, while the FY group operating margin ...

Fintel reports that on July 18, 2025, Jefferies upgraded their outlook for Abbott Laboratories (NYSE:ABT) from Hold to Buy.

Abbott debuts FreeStyle Libre 3 Plus in Canada, enhancing diabetes care with the world's smallest glucose sensor.

Usually, anxiety triggered by geopolitical tensions, monetary policy uncertainties, trade wars, and tariffs would be enough to prompt investors to adopt defensive strategies in the markets.

Abbott Laboratories ABT recently made its FreeStyle Libre 3 Plus sensor available to Canadians living with diabetes. This latest generation glucose monitoring device features the world's smallest ...

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.